Lorena Raquel Lerner Sells 3,568 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) insider Lorena Raquel Lerner sold 3,568 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the sale, the insider owned 27,559 shares in the company, valued at $283,582.11. The trade was a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Keros Therapeutics Stock Down 1.4%

NASDAQ:KROS traded down $0.15 during trading hours on Thursday, reaching $10.95. 203,071 shares of the company’s stock were exchanged, compared to its average volume of 339,802. The company has a market capitalization of $217.14 million, a P/E ratio of -2.96 and a beta of 0.99. Keros Therapeutics, Inc. has a 12 month low of $9.69 and a 12 month high of $22.55. The business’s 50-day simple moving average is $10.67 and its two-hundred day simple moving average is $11.90.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, sell-side analysts anticipate that Keros Therapeutics, Inc. will post -5.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. Leerink Partners decreased their price target on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. Zacks Research cut Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Wells Fargo & Company cut their price objective on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Tuesday, August 4th. Finally, Wall Street Zen lowered shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $20.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd boosted its position in Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares during the period. Legal & General Group Plc purchased a new stake in shares of Keros Therapeutics in the second quarter worth approximately $90,000. PDT Partners LLC purchased a new stake in shares of Keros Therapeutics in the second quarter worth approximately $122,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Keros Therapeutics during the first quarter worth approximately $129,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.